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Aims: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial,
a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel
fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with
iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inade-
quately controlled on a previous regimen of basal insulin alone or in combination with 1 or
2 oral glucose-lowering drugs.
Materials and Methods: In this exploratory analysis of LixiLan-L (N = 736), efficacy outcomes
were assessed within population subgroups derived from the following baseline characteristics:
glycated haemoglobin [HbA1c; <8%, ≥8% (<64, ≥64 mmol/mol)]; duration of T2DM (<10,
≥10 years); body mass index (<30, ≥30 kg/m2). Furthermore, the incidence of symptomatic
hypoglycaemia with plasma glucose ≤3.9 mmol/L (≤70 mg/dL) was also analysed according to
the same subgroups.
Results: Compared with the iGlar treatment group, patients treated with iGlarLixi showed con-
sistently greater reductions in HbA1c during the treatment period, with higher percentages of
patients achieving the HbA1c target level of <7% (<53 mmol/mol) in all of the subpopulations
tested (P < .0001 for all), having consistent mitigation of body weight gain and with no major
differences in the incidence of hypoglycaemia.
Conclusions: iGlarLixi consistently improved glycaemic control compared with iGlar in all base-
line characteristic subgroups of patients with T2DM inadequately controlled with insulin,
including difficult-to-treat subgroups of patients with long duration of diabetes, obesity and
high HbA1c.
Clinical trial number: NCT02058160 (clinicaltrials.gov).
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1 | INTRODUCTION
Current diabetes treatment guidelines suggest that if a patient with
type 2 diabetes mellitus (T2DM) does not achieve glycated haemo-
globin (HbA1c) targets despite treatment with basal insulin (usually
in combination with metformin and/or another oral drug), the
patient’s regimen should be intensified with the addition of either
mealtime insulin or a glucagon-like peptide-1 receptor agonist
(GLP-1 RA).1,2 The addition of mealtime insulin to a basal regimen,
while often effective at lowering glycaemia, can involve markedly
increasing the patient’s daily injection burden, and may be accom-
panied by an increased risk of weight gain and hypoglycaemia.
Adding a GLP-1 RA to a basal insulin regimen can augment glycae-
mic control with minimal additional risk of hypoglycaemia and with-
out adding to the risk of weight gain associated with insulin itself,
although GLP-1 RAs are often associated with gastrointestinal
adverse events. Lixisenatide (Lixi: Lyxumia, Sanofi, Paris, France;
Adlyxin, Sanofi, Bridgewater, NJ, USA) is a once-daily prandial
GLP-1 RA with a robust postprandial plasma glucose (PPG)-
lowering effect, which is predominantly driven by delayed gastric
emptying and reductions in glucose-dependent glucagon release.3–6
The rationale for combining basal insulin with Lixi is that glycae-
mic control can be enhanced via a dual, complementary mechanism
of action offered by the two components, each of which has its
own distinct mechanism: basal insulin principally lowers the
patient’s fasting plasma glucose (FPG), while Lixi acts predomi-
nantly by lowering PPG.
The combination of Lixi and basal insulin glargine 100 U (iGlar) as
separate injections has been shown to be more effective than basal
insulin alone.7,8 iGlarLixi, a titratable fixed-ratio combination of iGlar
and Lixi, was developed for administration as a single daily injection,
and therefore has the potential to increase glycaemic control without
the need for additional injections.
The LixiLan-L trial showed that iGlarLixi achieved superior gly-
caemic control compared with iGlar in patients with advanced T2DM
whose glycaemia was not adequately controlled on basal insulin in
combination with up to two oral glucose-lowering drugs. iGlarLixi
mitigated the weight gain observed with iGlar, did not have additional
risk of hypoglycaemia compared with iGlar alone, and had a lower
rate of gastrointestinal side-effects compared with data from prior
studies of Lixi.9 Similarly, in the LixiLan-O trial, iGlarLixi was superior
to iGlar and to Lixi in insulin-naïve patients with T2DM inadequately
controlled with metformin  a second oral glucose-lowering drug.10
Trials of another single injection combination of a GLP-1 RA with
basal insulin, in similar populations to that of the present study, also
found additional benefit of the combination over basal insulin
alone.11,12
As patients with T2DM exhibit diverse disease characteristics, it
is important to determine the efficacy and safety of new treatment
options across the patient spectrum.13–15 Therefore, exploratory
subpopulation analyses of data from the LixiLan-L trial were per-
formed to assess the impact of patients’ baseline characteristics of
HbA1c, disease duration and body mass index (BMI) on clinical
outcomes.
2 | MATERIALS AND METHODS
2.1 | Trial design
The full methodology of the LixiLan-L trial (NCT02058160) has been
described previously in detail.9 Briefly, LixiLan-L was an open-label,
randomized, parallel-group, multinational, multicentre, 2-arm trial with
treatment duration of 30 weeks. The trial was designed and moni-
tored in accordance with Good Clinical Practice, the International
Conference on Harmonization, and the Declaration of Helsinki. Insti-
tutional review boards or ethics committees at each study site
approved the protocol. Each patient gave written informed consent.
2.2 | Trial population
Patients (≥18 years) with T2DM diagnosed at least 1 year prior to
screening were eligible for inclusion if they had been treated with
basal insulin for at least 6 months before screening and were under a
stable regimen of 15 to 40 U/d (20%) for at least 2 months prior to
screening. The permitted oral glucose-lowering therapies (a maximum
of two was allowed) were metformin (>1500 mg/d or maximum-
tolerated dose), a sulphonylurea, a glinide, a sodium-glucose cotran-
sporter 2 inhibitor or a dipeptidyl peptidase 4 inhibitor. Doses of any
oral glucose-lowering therapies (if taken) also had to have been stable
during the 3 months before screening.
2.3 | Randomization and interventions
Eligible patients entered a 6-week run-in phase during which any oral
glucose-lowering drug other than metformin was stopped, patients
were switched to iGlar (if they had previously been receiving another
basal insulin), and the daily dose of iGlar was titrated and/or stabi-
lized for all patients. To enter the subsequent treatment period,
patients were required to have an HbA1c level of 7% to 10% (53 to
86 mmol/mol), mean fasting self-measured plasma glucose
≤7.8 mmol/L (≤140 mg/dL), iGlar daily dose 20 to 50 U (inclusive),
calcitonin ≤5.9 pmol/L, and amylase and/or lipase levels <3× the
upper limit of normal at the end of the run-in period. Patients who
met these requirements were then randomized in a 1:1 ratio to
receive once-daily open-label treatment with either iGlarLixi or iGlar
for 30 weeks. Titration algorithms and criteria for rescue medication
have been described previously.9 Briefly, both treatments were
titrated to FPG <100 mg/dL (<5.6 mmol/mol) up to a maximum dose
of 60 U of insulin/day. iGlarLixi was administered via two pen injector
options: pen A delivered a ratio of 2 U iGlar to 1 μg Lixi over a 10 to 40 U
iGlar dose range; pen B delivered a ratio of 3 U iGlar to 1 μg Lixi over a
30 to 60 U iGlar dose range. The dose of iGlarLixi was titrated as per the
patient’s insulin requirement, and the accompanying Lixi dose was driven
by the applied ratio, with a maximum dose of 20 μg/d.
2.4 | Subpopulation analysis
The exploratory subpopulation analysis presented here was designed
to evaluate the potential impact of baseline disease characteristics on
the clinical outcomes of the LixiLan-L trial; participants were split into
subpopulations according to the following baseline characteristics:
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randomization strata of HbA1c at week −1 in the trial protocol [<8%
or ≥8% (<64 or ≥64 mmol/mol); prespecified cut-offs in the trial pop-
ulation, with 64 mmol/mol also being the approximate baseline mean
for the study population]; duration of T2DM [<10 or ≥10 years: the
approximate median duration for the trial population (categories
determined post hoc)]; and BMI (<30 or ≥30 kg/m2; prespecified cut-
offs in the trial protocol). Clinical endpoints, from baseline to week
30, were analysed post hoc by the above subpopulation categories:
change in HbA1c from baseline to week 30 (prespecified for HbA1c
and BMI categories); FPG; 2-h PPG levels during a standardized
breakfast meal test; body weight; and the proportion of patients who
achieved HbA1c <7% (<53 mmol/mol) were also recorded for each
subpopulation category. Documented symptomatic hypoglycaemia,
defined as an event with typical symptoms of hypoglycaemia that
were accompanied by measured plasma glucose concentration of
≤3.9 mmol/L (≤70 mg/dL), was also analysed per subpopulation.
2.5 | Statistical methods
A 2-way analysis of variance with last observation carried forward
was used to assess comparisons between treatment groups and sub-
populations for continuous data. Comparisons between treatment
groups and subpopulations for categorical data were based on
Cochran–Mantel–Haenszel tests. Analysis of covariance was carried
out in accordance with prior publications on this study.9 Heterogene-
ity was tested using the 1 degree of freedom contrast corresponding
to the test of treatment by subgroup interaction.
3 | RESULTS
3.1 | Main study analysis
A total of 736 patients were randomized in the LixiLan-L trial: 367 to
iGlarLixi and 369 to iGlar. Demographics and baseline characteristics
were similar across the two treatment groups, and have been pub-
lished previously with the primary study results.9 In the main study
analysis, the least squares mean HbA1c change from baseline was
significantly greater with iGlarLixi [−1.1% (−12 mmol/mol)] than with
iGlar [−0.6% (−6.6 mmol/mol)]. In total, 55% of iGlarLixi patients
reached HbA1c <7% (<53 mmol/mol) compared with 30% of iGlar
patients.9 iGlarLixi also demonstrated significant reductions in 2-h
PPG following a standardized liquid breakfast meal compared with
iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and
increased by 0.7 kg with iGlar (P < .0001). These improvements were
accompanied by no increased risk of hypoglycaemia with iGlarLixi
compared with iGlar.
Similar numbers of patients from the iGlarLixi and iGlar treatment
groups fell into each of the subgroups based on baseline HbA1c, dia-
betes duration and BMI, allowing for balanced subgroup analyses.
3.2 | Glycaemic control according to baseline
HbA1c, duration of T2DM and BMI
Table 1 shows efficacy analyses in subpopulations based on baseline
HbA1c [<8% or ≥8% (<64 or ≥64 mmol/mol), duration of T2DM (<10
or ≥10 years) and BMI (<30 or ≥30 kg/m2)]. In all subpopulations,
reductions from baseline to week 30 in HbA1c were consistently
greater with iGlarLixi than with iGlar (P < .0001). Within both the
iGlarLixi and the iGlar treatment groups, patients with baseline
HbA1c ≥8% (≥64 mmol/mol) achieved significantly greater HbA1c
reductions than those with baseline HbA1c <8% (<64 mmol/mol;
P < .001). In each of the subpopulations based on baseline HbA1c,
T2DM duration and BMI, the proportion of patients who achieved
target HbA1c <7% (<53 mmol/mol) was higher with iGlarLixi than
with iGlar alone (P < .0001; Figure 1A–C).
Similar to the primary LixiLan-L analyses, there were no signifi-
cant differences between the 2 treatment groups in mean change in
FPG from baseline to week 30 for each subpopulation, indicating the
consistent titration of the basal insulin components in the study.
However, also in line with the primary results, significant reductions
from baseline to week 30 in 2-h PPG during the standardized meal
test were observed with iGlarLixi vs iGlar across subpopulations
(P < .0001). Within both the iGlarLixi and the iGlar treatment groups,
patients with baseline HbA1c ≥8% (≥64 mmol/mol) achieved signifi-
cantly greater reductions in 2-h PPG than those with baseline HbA1c
<8% (<64 mmol/mol; P < .001).
3.3 | Body weight change by subpopulation
Consistent with the primary LixiLan-L results, iGlarLixi mitigated body
weight gain compared with iGlar alone across all baseline characteris-
tic subpopulations (P ≤ .001; Figure 2A–C). Irrespective of baseline
HbA1c, T2DM duration or BMI, iGlarLixi treatment resulted in mean
body weight reduction (up to −0.9 kg), whereas iGlar treatment
resulted in body weight gain (up to +1.1 kg).
3.4 | Hypoglycaemia by subpopulation
The incidence of hypoglycaemia [defined as plasma glucose
≤3.9 mmol/L (≤70 mg/dL)] varied slightly between the HbA1c, T2DM
duration and BMI subpopulations; however, no significant differences
were observed (Figure 3A–C). The corresponding number of events
per patient-year was numerically lower in the iGlarLixi group than in
the iGlar group in each of the subpopulation analyses.
4 | DISCUSSION
The subpopulation analyses of the LixiLan-L trial presented here
found that iGlarLixi was effective in all baseline subpopulations
tested, including in patients with higher HbA1c, longer duration of
diabetes and higher BMI. The iGlarLixi treatment group showed con-
sistently greater glycaemic control and higher percentages of patients
reaching the HbA1c target than the iGlar group across all of the sub-
populations. The incidence of hypoglycaemia varied between subpo-
pulations, but no substantial differences were observed between
therapeutic groups. Additionally, weight gain was mitigated in the
iGlarLixi group compared with iGlar, regardless of baseline HbA1c,
T2DM duration or BMI. The results of these subpopulation analyses
are consistent with those of the main LixiLan-L trial.9
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TABLE 1 Subpopulation analyses according to baseline HbA1c, duration of T2DM and BMI
Subpopulation analyses according to baseline HbA1c
iGlarLixi (fixed-ratio combination) iGlar (insulin glargine 100 U)
HbA1c <8% HbA1c ≥8% HbA1c <8% HbA1c ≥8%
HbA1c (%) Baseline (n) 7.5  0.3 (165) 8.6  0.5 (199) 7.4  0.4 (163) 8.6  0.5 (201)
Week 30 6.7  0.8 7.2  0.9 7.1  0.8 7.8  0.9
Mean change at week 30 −0.8  0.8 −1.4  0.9a −0.3  0.8 −0.8  0.9a
Mean difference  SEb −0.5  0.1 −0.5  0.1
P-value <.0001 <.0001
FPG (mmol/L) Baseline (n) 7.3  1.9 (165) 7.3  2.0 (199) 6.9  1.9 (163) 7.6  2.2 (201)
Mean change at week 30 −0.6  2.6 −0.4  2.7 −0.3  2.7 −0.8  2.7
Mean difference  SEb −0.3  0.3 0.5  0.3
P-value .370 .080
2-h PPG (mmol/L) Baseline (n) 13.9  3.4 (152) 15.7  4.0 (180) 13.7  3.2 (151) 16.0  3.7 (189)
Mean change at week 30 −4.6  3.9 −5.3  4.9a −0.8  4.2 −2.2  4.2a
Mean difference  SEb −3.8  0.5 −3.1  0.5
P-value <.0001 <.0001
Daily iGlar dose at week 30 (U) n 165 200 163 202
Mean  SD 45.6  12.1 45.8  13.5 44.8  13.2 48.1  11.8
Subpopulation analyses according to T2DM duration
iGlarLixi (fixed-ratio combination) iGlar (insulin glargine 100 U)
<10 years ≥10 years <10 years ≥10 years
T2DM duration (years) Baseline (n) 6.7  2.1 (167) 16.6  5.7 (199) 6.1  2.5 (150) 16.3  5.7 (214)
HbA1c (%) Baseline (n) 8.0  0.7 (166) 8.1  0.7 (198) 8.0  0.7 (150) 8.1  0.7 (213)
Week 30 6.9  0.9 7.0  0.9 7.4  1.0 7.6  0.9
Mean change at week 30 −1.1  0.9 −1.1  0.9 −0.6  0.9 −0.6  0.8
Mean difference  SEb −0.5  0.1 −0.5  0.1
P-value <.0001 <.0001
FPG (mmol/L) Baseline (n) 7.5  2.0 (166) 7.2  1.9 (198) 7.3  1.9 (150) 7.3  2.2 (213)
Mean change at week 30 −0.9  2.5 −0.1  2.8a −0.6  2.5 −0.6  2.8
Mean difference  SEb −0.3  0.3 0.5  0.3
P-value .352 .067
2-h PPG (mmol/L) Baseline (n) 14.6  3.8 (151) 15.1  3.9 (181) 15.0  3.4 (138) 15.0  3.9 (201)
Mean change at week 30 −4.8  4.6 −5.1  4.4 −1.8  3.8 −1.4  4.5
Mean difference  SEb −3.0  0.5 −3.6  0.4
P-value <.0001 <.0001
Daily iGlar dose at week 30 (U) n 166 199 150 214
Mean  SD 46.4  12.8 45.1  12.9 48.6  12.4 45.2  12.4
Subpopulation analyses according to BMI
iGlarLixi (fixed-ratio combination) iGlar (insulin glargine 100 U)
BMI <30 kg/m2 BMI ≥30 kg/m2 BMI <30 kg/m2 BMI ≥30 kg/m2
BMI (kg/m2) Baseline (n) 27.3  1.9 (156) 34.3  2.8 (210) 27.2  2.0 (156) 33.8  2.8 (209)
HbA1c (%) Baseline (n) 8.1  0.7 (155) 8.1  0.7 (209) 8.1  0.8 (156) 8.1  0.7 (208)
Week 30 7.0  0.9 7.0  0.9 7.6  1.0 7.4  0.8
Mean change at week 30 −1.1  0.9 −1.1  0.9 −0.5  0.9 −0.6  0.9
Mean difference  SEb −0.6  0.1 −0.5  0.1
P-value <.0001 <.0001
FPG (mmol/L) Baseline (n) 7.0  2.0 (155) 7.6  1.8 (209) 6.9  2.2 (156) 7.6  1.9 (208)
Mean change at week 30 −0.2  2.8 −0.6  2.6 −0.3  3.0 −0.8  2.4
Mean difference  SEb 0.1  0.3 0.2  0.3
P-value .739 .516
2-h PPG (mmol/L) Baseline (n) 14.7  3.7 (135) 15.0  3.9 (197) 14.9  3.9 (143) 15.0  3.5 (197)
Mean change at week 30 −5.0  4.7 −4.9  4.3 −0.8  4.5 −2.1  3.9a
(Continued )
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With a mean diabetes duration of 12 years and mean BMI of
31 kg/m2, the population of the LixiLan-L trial represents a group of
patients with T2DM that is challenging to treat successfully in the
clinical setting. These are overweight or obese patients who have
long-standing disease, and have progressed to a stage where they
require more than oral glucose-lowering drugs and injected basal
insulin to maintain glycaemic control. By the time of screening for the
LixiLan-L trial, the study patients had a mean HbA1c of 8.5%
(69 mmol/mol), despite having been treated for several years with
basal insulin and oral drugs.9 In this trial, treatment with iGlar alone
TABLE 1 Continued
Subpopulation analyses according to BMI
iGlarLixi (fixed-ratio combination) iGlar (insulin glargine 100 U)
BMI <30 kg/m2 BMI ≥30 kg/m2 BMI <30 kg/m2 BMI ≥30 kg/m2
Mean difference  SEb −4.2  0.5 −2.8  0.4c
P-value <.0001 <.0001
Daily iGlar dose at week 30 (U) n 155 210 156 209
Mean  SD 40.6  12.4 49.5  11.9 42.8  12.7 49.5  11.6
Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; iGlar, insulin glargine; Lixi, lixisenatide; PPG, postpran-
dial plasma glucose; SE, standard error; T2DM, type 2 diabetes mellitus.
All data are mean  SD unless stated otherwise.
a Between-subpopulation comparison P < .05.
b Mean difference iGlarLixi vs iGlar. Treatment comparison P-values based on 2-factor analysis of variance.
c Heterogeneity P-value = .012. Value is based on a single degree of freedom contrast of treatment differences between subgroups.
HbA1c <8% (<64 mmol/mol) HbA1c ≥8% (≥64 mmol/mol)A
B
C
FIGURE 1 Percentages of patients who achieved HbA1c target <7%
(<53 mmol/mol) for baseline A, HbA1c; B, diabetes duration and C,
BMI subpopulations. *Treatment comparisons within subgroups are
based on 2-factor Cochran–Mantel–Haenszel. An adjustment was
made for the treatment differences based on the randomization
strata. BMI, body mass index; HbA1c, glycated haemoglobin; T2DM,
type 2 diabetes mellitus
HbA1c <8% (<64 mmol/mol) HbA1c≥8% (≥64 mmol/mol)A
B
C
FIGURE 2 Mean weight change for baseline A, HbA1c; B, diabetes
duration and C, BMI subpopulations. *Treatment comparisons within
subgroups are based on 2-factor Cochran–Mantel–Haenszel. BMI,
body mass index; HbA1c, glycated haemoglobin; T2DM, type
2 diabetes mellitus
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reduced the mean HbA1c to 7.5% (58 mmol/mol), which, considering
the patients’ history of basal insulin treatment, was a marked
improvement and consistent with other trials where basal insulin was
titrated.16 However, treatment with iGlarLixi resulted in even further
improvements in HbA1c [reduction to 6.9% (52 mmol/mol) for overall
population and to ~7.0% (53 mmol/mol) for each subgroup analysed],
while also providing both fasting and postprandial glycaemic control
with a single injection formulation, which greatly simplifies the thera-
peutic approach.
The rationale for the combination of iGlar with Lixi is that the
two agents have complementary mechanisms of action, with the
insulin component mainly acting on the FPG, and the Lixi component
reducing PPG levels. Such complementary mechanisms may be partic-
ularly beneficial to patients with long-standing disease and high
HbA1c despite basal insulin treatment, especially those with uncon-
trolled PPG. As observed in the present analysis, iGlarLixi significantly
reduced PPG compared with iGlar alone, irrespective of baseline
HbA1c, T2DM duration or BMI. This is consistent with the known
prandial mechanism of action of Lixi, which has been seen in trials to
lower PPG by between 3 and 8 mmol/L (54 and 144 mg/dL).7,8,17–20
This prandial effect, which is an important contributor to the overall
glucose-lowering effect of Lixi, is mediated by a delay in gastric emp-
tying after a meal.6 The delay in gastric emptying is preserved in
patients with diabetes, even after the loss of much of their β-cell
function, allowing such patients to maintain a meaningful response to
Lixi treatment.
The primary efficacy endpoint was also analysed for other pre-
specified subgroups (race, ethnicity, age group, sex, metformin use at
screening, and number of oral drugs used at screening). Although the
data are not presented here, the results of all these analyses were
consistent with the overall analysis.
The results of the current exploratory analysis should be inter-
preted with caution. The limitations of the LixiLan-L trial and this sub-
sequent post hoc analysis include the open-label design, the relatively
short 30-week duration, and inclusion criteria that may not com-
pletely represent a “real world” population. These limitations may in
the future, at least in part, be addressed in studies of longer duration
in populations of interest.
In summary, this subgroup analysis of the LixiLan-L trial acknowl-
edges that, even within a population of patients with long-standing
diabetes, there are variations between patients in terms of disease
characteristics. Therefore, while treatment with iGlarLixi was effica-
cious in the overall LixiLan-L population, it was important to deter-
mine whether benefit would be seen across this spectrum of patient
characteristics. The results presented here show that iGlarLixi was
beneficial in all of the subgroups studied in the LixiLan-L trial, regard-
less of the patients’ demographics and initial clinical characteristics.
The glycaemic control was achieved without an increased risk of
hypoglycaemia, even in patients with longer duration of disease and
low BMI, subgroups that may be considered to be more vulnerable to
hypoglycaemic episodes. These findings serve to validate further the
concept that the fixed-ratio titratable combination iGlarLixi is a suita-
ble therapeutic option across a range of patients with differing char-
acteristics who are inadequately controlled on basal insulin
treatment.
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